Advancing standards of care for Pulmonary Embolism

Pulmonary Embolism

Advancing standards of care for intermediate-high to high-risk patients of pulmonary Embolism

Advancing standards of care for Pulmonary Embolism 

Each year nearly one million patients in the U.S. and Europe are affected by Pulmonary Embolism (PE), a blood clot causing a blockage in one or more pulmonary arteries within the lungs.

In intermediate-high risk or high-risk cases of PE, the blockage may lead to a strain on the heart’s ability to pump blood through the lungs and can be fatal. The current standard of care for PE is anticoagulation, though there are disparate guidelines to direct safe and effective treatment of patients with intermediate-high-risk PE.

Boston Scientific aims to make ultrasound-accelerated thrombolysis the new standard of care for patients with intermediate-high-risk PE. Minimally invasive, this 15-minute procedure requires lower lytic doses, limits bleeding, and has proven patient outcomes.1

Symptoms of pulmonary embolism

Pulmonary embolism (PE) is a significant cause of death for hospitalised patients– directly causing or contributing to 15% of hospital deaths.2

Learn more about the symptoms of Pulmonary Embolism
PE causes or contribues to 15% of all hospital deaths

ESC Guidelines provide a roadmap for diagnosis

Pulmonary Embolism can be immediately fatal, but studies show that mortality can be reduced from 30% to <5% with appropriate diagnosis and treatment.1,3

Learn more about ESC Guidelines
reduce mortaliy from PE

Every 60 seconds someone is diagnosed with Pulmonary Embolism.
It takes a united front to take action against this complex disease.

Clinical evidence

The use of interventional treatment in PE is backed by patient outcomes and long-term clinical evidence.
Recent studies like HI-PEITHO and KNOCKOUT will help advance standards of care for PE patients.

Get the clinical overview about EKOSTM ultrasound-assisted thrombolysis

PERT for Pulmonary Embolism

Multidisciplinary Pulmonary Embolism Response Teams (PERT) are critical to ensuring consistent patient treatment and outcomes across your hospital for PE patients.

Learn about PERT best practices

What are the main challenges in building a centre specialised in PE treatment?

Oct 08, 2020 (Time 6 min55 )

Interview with Professor Laurent Bonello, Head of ICU and PERT Team University Hospital Nord Marseille, France

 

Learn to diagnose and treat Pulmonary Embolism

Pulmonary Embolism is responsible for 15% of hospital deaths. Boston Scientific is committed to helping practitioners across medical specialties learn more about Pulmonary Embolism – how to diagnose it, how to treat it, and when it’s right to intervene.

Get the details about the BSC learning program on Pulmonary Embolism

How to diagnose and choose right treatment for the patients suffering from Pulmonary Embolism

Sep 24, 2020  (Time 2 min)

Interview with Professor Nils Kucher, Professor of Angiology, Director University Clinic of Angiology, Cardiovascular Division, University Hospital Zurich, Switzerland

 

How to build the right pathway for patients with Pulmonary Embolism?

Sep 23, 2020 (Time 4 min)

Interview with Dr Nick Murch, Consultant Physician in Acute Medicine, Royal Free London, UK

 

EKOS™ Endovascular System 

EKOS™ was the first interventional device indicated for the treatment of Pulmonary Embolism. It is also used to treat deep vein thrombosis (DVT) and peripheral arterial occlusion (PAO).

Get full product details

References:
1. Tapson, Victor, et al., “A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The OPTALYSE PE Trial.” JACC: Cardiovascular Interventions Jul 2018, 11 (14) 1401-10
2. Beers, M.H., et al., The Merck Manual of Diagnosis and Therapy. 18th edition. Whitehouse Station, NJ: Merck Research Laboratories, 2006: 412-22, 427, 2081-2
3. Banovac “Reporting standards for endovascular treatment of pulmonary embolism.” J Vasc Interv Radiol, 2010; 21:44-53

Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.